Renaissance Technologies LLC Has $38.24 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Renaissance Technologies LLC lessened its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 5.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,954,800 shares of the company’s stock after selling 163,400 shares during the period. Renaissance Technologies LLC owned about 0.09% of Takeda Pharmaceutical worth $38,235,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rise Advisors LLC acquired a new position in shares of Takeda Pharmaceutical in the first quarter worth approximately $26,000. Principal Securities Inc. acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter worth approximately $28,000. GAMMA Investing LLC boosted its stake in shares of Takeda Pharmaceutical by 50.9% in the 1st quarter. GAMMA Investing LLC now owns 2,864 shares of the company’s stock valued at $40,000 after purchasing an additional 966 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Takeda Pharmaceutical during the second quarter worth $59,000. Finally, Blue Trust Inc. increased its position in shares of Takeda Pharmaceutical by 74.0% during the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after buying an additional 2,330 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

TAK stock opened at $14.82 on Thursday. The company has a quick ratio of 0.74, a current ratio of 1.26 and a debt-to-equity ratio of 0.65. The firm has a market cap of $47.16 billion, a price-to-earnings ratio of 26.95, a PEG ratio of 0.27 and a beta of 0.54. The company’s fifty day simple moving average is $14.27 and its 200 day simple moving average is $13.75. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $16.39.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. The company had revenue of $7.75 billion for the quarter. On average, analysts expect that Takeda Pharmaceutical Company Limited will post 1.63 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.